BIODIEM LTD
ABN 20 096 845 993
Level 4,
100 Albert Rd,
South Melbourne, Victoria, 3205
Australia
Phone: +613 9692 7240
Web: www.biodiem.com

Announcement

Australian Life Science Investment Showcase Presentation in San Francisco

Melbourne, 23 June 2014:

BioDiem's CEO, Julie Phillips presented at the Australian Life Science Investment Showcase held in San Francisco on Friday 20 June 2014. The event was timed to precede the enormous BIO 2014 International Convention to be held in San Diego this week. The Showcase event was designed to spotlight and celebrate the achievements and opportunities in the Australian biotech sector. The BioDiem presentation focused on BioDiem's BDM-I and the opportunity presented by the antimicrobial for collaboration and investment.

ENDS

About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company developing vaccines and antimicrobials targeting treatment and prevention of infectious diseases and related cancers. BioDiem's business model is to generate income from partnerships including with other vaccine development companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine used for seasonal and pandemic influenza vaccines and is given intranasally. For additional information, please visit www.biodiem.com

Further information

Julie Phillips, Chief Executive Officer
BioDiem Ltd
Phone +61 3 9692 7240
Email jphillips@biodiem.com

BioDiem

Therapies for major infectious diseases and related cancers

Australian Life Science Investment Showcase:
San Francisco 20th June 2014

Julie Phillips, CEO
jphillips@biodiem.com

Safe Harbour Statement

This presentation is provided to you for information purposes only and should not be construed as an offer, and shall not form part of an offer, or solicitation to buy or sell any securities or derivatives. It should not be considered as an invitation to subscribe for or purchase any securities in BioDiem Limited. or as an inducement to make an offer or invitation with respect to those securities. No agreement to subscribe for securities in BioDiem Limited will be entered into on the basis of this presentation.

To the maximum extent permitted by applicable laws, BioDiem Limited and its affiliates make no representation and can give no assurance, guarantee or warranty, express or implied, as to, and take no responsibility for the authenticity, validity, accuracy, suitability or completeness of, or any errors in or omission, from any information, statement or opinion contained in this presentation.

The contents of this presentation are confidential. The presentation is being provided to you on the condition that you do not reproduce or communicate it to, or disclose it to, or discuss it with, any other person without the prior written permission of BioDiem Limited.

Agenda

- **Company Overview**
- **Challenges**
- **BDM-I Antimicrobial**
- **BDM-I Opportunity**

Company Overview

Australian unlisted public company

As at April 30 2014	
Market Cap	~ $9 M
Shares	163,082,800
Shareholders	919
Options	18,587,417

Hugh Morgan AC



Chairman

Julie Phillips

CEO

Dr Larisa Rudenko

Non-executive Director

Dr Arthur Li

Non-executive Director

Don Brooks

Non-executive Director

Business Model



Business Model



Business Model



Phase I trials
Testing the drug on healthy volunteers

Phase II trials
Testing the drug on a small number of patients with the disease

Phase III trials
Testing the drug on hundreds/thousands or patients with the disease

Global partnering & commercialisation network



Key technologies

Target		Core Technology
Influenza vaccines (seasonal and pandemic)	→	LAIV vaccine – licensed in multiple countries, further opportunities being pursued
Vaccine development platforms nasopharyngeal carcinoma, TB targets	→	SAVINE technology, LAIV viral vector technologies for novel therapeutic vaccines
Infectious disease therapies	→	BDM-I antimicrobial compound

BioDiem

Challenges

Invasive Fungal Infection after Natural Disasters

Kaitlin Benedict and Benjamin J. Park

Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 20, No. 3, March 2014

OXFORD JOURNALS

Clinical Infectious Diseases

Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America

Dr. Arjun Srinivasan: We've Reached "The End of Antibiotics, Period" FRONTLINE October 22, 2013, 9:29 pm ET

THE VERGE

Gonorrhea is about to become impossible to treat

Antibiotic resistance means the STD might soon spread more aggressively

Australia Network News

Calls for action on 'dire' drug-resistant TB threat in Asia and the Pacific

By Jemima Garrett

Posted Mon 14 Apr 2014, 7:05pm AEST

Bulletin of the World Health Organization

Race against time to develop new antibiotics

CBCnews | Health

Superbug threat as grave as climate change, say scientists

'The international response has been feeble'

Thomson Reuters Posted: May 23, 2014 10:53 AM ET | Last Updated: May 23, 2014 10:53 AM ET

BioDiem

Challenges

Increasing resistance

To antibiotics – major concern healthcare systems worldwide

Hard to treat

Fungal infections, affecting vulnerable patients

Increase in prevalence

Due to climate change and vector movements.

Product pipelines diminish

Large Pharma focus on innovation, as product pipelines diminish

BioDiem

BDM-I: Antimicrobial



Spectrum of activity

Invasive and superficial fungal infections

Some species of

- *Candida*
- *Cryptococcus*
- *Scedosporium*
- *Pneumocystis*

Drug-resistant tuberculosis & gonorrhea

- *Mycobacterium tuberculosis*
- *Neisseria gonorrhoea*

Some protozoal infections

- *Trichomonas vaginalis; Plasmodium falciparum*

and others…

Novel mechanism of action

Inhibits new target

Protein Tyrosine Phosphatases (PTPs)

- Involved in cell signalling
- Mimics tyrosine



Heterogeneity of PTP function explains

- Selectivity within species
- Difference in function in mammalian cells

Antimicrobial spectrum

Unusually broad spectrum -
Some ***but not all*** bacteria, fungi, and protozoa. Not viruses.

Bacteria	Most active against G+ve cocci/rods; some non-enteric G-ve *Relatively low activity against Gram negative enteric rods*
Fungi	Active against some *Candida*, *Scedosporium,* dermatophytic fungi and other pathogens
Protozoa	Activity against *Plasmodium* & *Trichomonas*
Viruses	*No activity against viruses known to use PTP in the infection cycle (HIV, HSV). No enhancement of infection.*

BioDiem

In vitro activity

Group		(µg/ml)	Group		(µg/ml)
Fungi	MIC90 *C. glabrata*	* 1	**G-ve bacteria**	MIC *Neisseria gonorrhoeae*	2
	MIC90 *C. glabrata*	** 2		MIC *Campylobacter jejuni*	0.5 -2
	MIC90 *Coccidiodes spp.*	0.25*		Other bacteria - potential biological weapons	
	MIC90 *Coccidiodes spp.*	0.25**			
	IC50 *P.carinii*	<0.1***	**Parasite**	*Schistosomiasis japonicum*	
	IC50 *P. murina*	0.174***		LC50 Adults (5 days)	
				LC50 Schistosomulae (24 hrs)	
	MIC *Scedosporium prolificans* (three strains)	1-2		*Schistosomiasis masoni*	
				LC50 Adults (5 days)	
				LC50 Schistosomulae (8hrs)	

*50% Inhibition Endpoint
**100% Inhibition Endpoint
*** (based on %reduction ATP at Day3)

Adjunct to direct killing

Inhibition of virulence factors:

- Motility (*Proteus*, *C. difficile* and *Campylobacter jejuni)*
- Pigment formation (*Serratia marcescens)*
- Endospore formation (*Bacillus* spp)

Current preliminary *in vitro* assays show

- inhibition of biofilm formation in *S. aureus* & *S. epidermidis*
- inhibition of adherence and invasion of gut epithelial cells by

  Clostridium difficile & *Campylobacter jejuni*

Market Size Potential



Poised for proof-of-concept

Product	Disease Targets	Current Partners	Development Status
BDM-I	Tuberculosis & bioterrorism	US govt backed research institutions	Successful screening result: preparation for *in vivo* testing
	Pneumocystis	US govt backed research institutions	Successful screening result: preparation for *in vivo* testing
	Scedosporium	Australian site	Successful screening result: seeking disease models

Further mechanism of action exploration

Analogue development

Formulation for proof-of-concept studies ➔ multiple ROA options

BioDiem

Potential Product Range









"*Generating Antibiotic Incentives Now*" legislation

BioDiem

GAIN: How a New Law is Stimulating the Development of Antibiotics

May 28, 2014 | Project: Antibiotics and Innovation Project

On July 9, 2012, the Generating Antibiotic Incentives Now, or GAIN, provisions were signed into law by President Barack Obama as part of the Food and Drug Administration Safety and Innovation Act. This bipartisan legislation extends by five years the exclusivity period during which certain antibiotics—those that treat serious or life-threatening infections—can be sold without generic competition. This additional period of exclusivity increases the potential for profits from new antibiotics by giving innovative companies more time to recoup their investment costs.

"GAIN seeks to increase antibiotics' commercial value…."

BDM-I Opportunity



Complete formulation studies

BDM-I testing in animal models

Clinical trial in orphan disease

Next steps:

- Proprietary formulation (incl for different ROA)
- *In vivo* testing and POC
- Orphan drug application

Opportunity

- Global problem in infectious disease

- BDM-I has
  - Activity against important pathogens
  - Novel mechanism of action; granted patents
  - Collaborations in place with world class facilities

- Commercial opportunity for product and pipeline development
  - Life threatening and other infections
  - Attractive incentives e.g. GAIN legislation

We seek investment & collaboration to develop BDM-I towards use for niche high value diseases and expanded product range

BioDiem

Therapies for major infectious diseases and related cancers

Australian Life Science Investment Showcase:
San Francisco 20th June 2014

Julie Phillips, CEO
jphillips@biodiem.com